JP2006508994A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006508994A5 JP2006508994A5 JP2004554480A JP2004554480A JP2006508994A5 JP 2006508994 A5 JP2006508994 A5 JP 2006508994A5 JP 2004554480 A JP2004554480 A JP 2004554480A JP 2004554480 A JP2004554480 A JP 2004554480A JP 2006508994 A5 JP2006508994 A5 JP 2006508994A5
- Authority
- JP
- Japan
- Prior art keywords
- formoterol
- roflumilast
- pharmaceutical
- daily dose
- lung disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims 11
- 229960002848 formoterol Drugs 0.000 claims 11
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 claims 11
- 229960002586 roflumilast Drugs 0.000 claims 11
- 208000019693 Lung disease Diseases 0.000 claims 6
- 238000009472 formulation Methods 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- 229940127557 pharmaceutical product Drugs 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02026505 | 2002-11-27 | ||
| PCT/EP2003/013275 WO2004047829A1 (en) | 2002-11-27 | 2003-11-26 | New synergistic combination comprising roflumilast and formoterol |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006508994A JP2006508994A (ja) | 2006-03-16 |
| JP2006508994A5 true JP2006508994A5 (OSRAM) | 2006-11-30 |
Family
ID=32338002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004554480A Pending JP2006508994A (ja) | 2002-11-27 | 2003-11-26 | ロフルミラスト及びホルモテロールを含有する新規の相乗組合せ |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US20060142308A1 (OSRAM) |
| EP (1) | EP1567139B1 (OSRAM) |
| JP (1) | JP2006508994A (OSRAM) |
| KR (1) | KR101071798B1 (OSRAM) |
| CN (1) | CN100346777C (OSRAM) |
| AT (1) | ATE399543T1 (OSRAM) |
| AU (1) | AU2003292120B2 (OSRAM) |
| BR (1) | BR0316451A (OSRAM) |
| CA (1) | CA2506962C (OSRAM) |
| CO (1) | CO5690570A2 (OSRAM) |
| CY (1) | CY1110369T1 (OSRAM) |
| DE (1) | DE60321953D1 (OSRAM) |
| DK (1) | DK1567139T3 (OSRAM) |
| EA (1) | EA009935B1 (OSRAM) |
| ES (1) | ES2309357T3 (OSRAM) |
| HR (1) | HRP20050579B1 (OSRAM) |
| IL (1) | IL168308A (OSRAM) |
| IS (1) | IS2575B (OSRAM) |
| MA (1) | MA27539A1 (OSRAM) |
| ME (1) | ME00489B (OSRAM) |
| MX (1) | MXPA05005437A (OSRAM) |
| NO (1) | NO334247B1 (OSRAM) |
| NZ (1) | NZ540659A (OSRAM) |
| PL (1) | PL216752B1 (OSRAM) |
| PT (1) | PT1567139E (OSRAM) |
| RS (1) | RS51081B (OSRAM) |
| SI (1) | SI1567139T1 (OSRAM) |
| TN (1) | TNSN05131A1 (OSRAM) |
| UA (1) | UA83018C2 (OSRAM) |
| WO (1) | WO2004047829A1 (OSRAM) |
| ZA (1) | ZA200503308B (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY140561A (en) | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
| DE602004023921D1 (de) | 2003-03-10 | 2009-12-17 | Nycomed Gmbh | Neues verfahren zur herstellung vonroflumilast |
| US8663694B2 (en) * | 2005-03-16 | 2014-03-04 | Takeda Gmbh | Taste masked dosage form containing roflumilast |
| DE102005030733A1 (de) * | 2005-07-01 | 2007-01-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen enthaltend langwirksame Beta-2-Agonisten und wenigstens einen weiteren Wirkstoff |
| EP2359826B1 (en) * | 2006-07-05 | 2013-10-30 | Takeda GmbH | Combination of HMG-COA reductase inhibitor rosuvastatin with a phosphodiesterase 4 inhibitor, such as roflumilast, roflumilast-N-oxide for the treatment of inflammatory pulmonary diseases |
| WO2013077830A1 (en) * | 2011-11-25 | 2013-05-30 | Mahmut Bilgic | Synergistilly active combinations of roflumilast and carmoterol |
| US20130172303A1 (en) * | 2012-01-03 | 2013-07-04 | Forest Laboratories Holdings Ltd. | Roflumilast compositions for the treatment of copd |
| CN110403922A (zh) | 2013-01-28 | 2019-11-05 | 理森制药股份公司 | 通过吸入罗氟司特n-氧化物治疗自身免疫、呼吸和/或炎性病症的方法 |
| CN104800214A (zh) * | 2014-01-27 | 2015-07-29 | 成都英诺新科技有限公司 | 一种罗氟司特吸入气雾剂复方及制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5795564A (en) * | 1991-04-05 | 1998-08-18 | Sepracor, Inc. | Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol |
| SI0706513T1 (en) * | 1993-07-02 | 2002-10-31 | Altana Pharma Ag | Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors |
| AU734122B2 (en) * | 1997-02-17 | 2001-06-07 | Takeda Gmbh | Compositions for the treatment of ARDS or IRDS containing 3-(cyclopropylmethoxy)-n-(3,5-dichloro-4-pyridinyl)-4- (difluoromethoxy)benzamide and lung surfactant |
| SI0975347T1 (sl) * | 1997-02-28 | 2008-08-31 | Nycomed Gmbh | Sinergistična kombinacija PDE inhibitorjev in agonistov adenilat ciklaze oziroma agonistov gvanil ciklize |
| US6624181B1 (en) * | 1997-02-28 | 2003-09-23 | Altana Pharma Ag | Synergistic combination |
| HUP0103160A3 (en) * | 1998-08-26 | 2002-11-28 | Smithkline Beecham Corp | Pharmaceutical compositions for treating pulmonary diseases containing pde4 inhibitor |
| US6303145B2 (en) * | 1999-05-10 | 2001-10-16 | Sepracor Inc. | (S,R) formoterol methods and compositions |
| HU229439B1 (hu) * | 1999-08-21 | 2013-12-30 | Takeda Gmbh | Roflumilast és salmeterol szinergetikus kombinációja |
| GB0103630D0 (en) * | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
| WO2002076933A1 (en) * | 2001-03-22 | 2002-10-03 | Glaxo Group Limited | Formailide derivatives as beta2-adrenoreceptor agonists |
| US7291608B2 (en) * | 2001-04-30 | 2007-11-06 | Glaxo Group Limited | Anti-inflammatory 17.β.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.α |
-
2003
- 2003-11-26 DE DE60321953T patent/DE60321953D1/de not_active Expired - Lifetime
- 2003-11-26 RS YUP-2005/0382A patent/RS51081B/sr unknown
- 2003-11-26 DK DK03767663T patent/DK1567139T3/da active
- 2003-11-26 BR BR0316451-9A patent/BR0316451A/pt not_active IP Right Cessation
- 2003-11-26 US US10/535,816 patent/US20060142308A1/en not_active Abandoned
- 2003-11-26 HR HRP20050579AA patent/HRP20050579B1/hr not_active IP Right Cessation
- 2003-11-26 PL PL377732A patent/PL216752B1/pl unknown
- 2003-11-26 EA EA200500774A patent/EA009935B1/ru not_active IP Right Cessation
- 2003-11-26 PT PT03767663T patent/PT1567139E/pt unknown
- 2003-11-26 MX MXPA05005437A patent/MXPA05005437A/es active IP Right Grant
- 2003-11-26 CN CNB2003801037450A patent/CN100346777C/zh not_active Expired - Fee Related
- 2003-11-26 CA CA2506962A patent/CA2506962C/en not_active Expired - Fee Related
- 2003-11-26 ES ES03767663T patent/ES2309357T3/es not_active Expired - Lifetime
- 2003-11-26 KR KR1020057009210A patent/KR101071798B1/ko not_active Expired - Fee Related
- 2003-11-26 AU AU2003292120A patent/AU2003292120B2/en not_active Ceased
- 2003-11-26 WO PCT/EP2003/013275 patent/WO2004047829A1/en not_active Ceased
- 2003-11-26 NZ NZ540659A patent/NZ540659A/en not_active IP Right Cessation
- 2003-11-26 EP EP03767663A patent/EP1567139B1/en not_active Expired - Lifetime
- 2003-11-26 UA UAA200505966A patent/UA83018C2/uk unknown
- 2003-11-26 AT AT03767663T patent/ATE399543T1/de active
- 2003-11-26 SI SI200331344T patent/SI1567139T1/sl unknown
- 2003-11-26 ME MEP-2008-782A patent/ME00489B/me unknown
- 2003-11-26 JP JP2004554480A patent/JP2006508994A/ja active Pending
-
2005
- 2005-04-25 ZA ZA200503308A patent/ZA200503308B/en unknown
- 2005-05-01 IL IL168308A patent/IL168308A/en not_active IP Right Cessation
- 2005-05-10 TN TNP2005000131A patent/TNSN05131A1/en unknown
- 2005-06-16 MA MA28343A patent/MA27539A1/fr unknown
- 2005-06-17 NO NO20052999A patent/NO334247B1/no not_active IP Right Cessation
- 2005-06-20 IS IS7898A patent/IS2575B/is unknown
- 2005-06-27 CO CO05062787A patent/CO5690570A2/es not_active Application Discontinuation
-
2008
- 2008-09-17 CY CY20081101017T patent/CY1110369T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6790465B2 (en) | Composition and method for treating snoring | |
| JP2023041862A5 (OSRAM) | ||
| JP2022180461A5 (OSRAM) | ||
| JP2003292443A5 (OSRAM) | ||
| NZ585856A (en) | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease | |
| JP6762931B2 (ja) | 経鼻組成物と該経鼻組成物の使用方法の改善 | |
| MX2009009131A (es) | Mejoras en y con relacion a composiciones medicinales. | |
| JP2009269923A5 (OSRAM) | ||
| NZ585857A (en) | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease | |
| JP2007520506A5 (OSRAM) | ||
| WO2007012019A3 (en) | Medicaments containing famotidine and ibuprofen and administration of same | |
| JP2002528502A5 (OSRAM) | ||
| JP2005508963A5 (OSRAM) | ||
| WO2005041921A3 (en) | Dry powder compositions for inhalation therapy comprising calcium stearate, medical devices therefor | |
| CA2519175A1 (en) | A method of treating a systemic disease | |
| MXPA05009629A (es) | Composiciones que contienen trospio. | |
| JP2004537500A5 (OSRAM) | ||
| GB2430623A (en) | Medicaments for treating chronic respiratory disease | |
| JP2006508994A5 (OSRAM) | ||
| JP2016505050A5 (OSRAM) | ||
| RU2008119454A (ru) | Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом | |
| JP2011500589A5 (OSRAM) | ||
| CA2506962A1 (en) | Synergistic combination comprising roflumilast and formoterol | |
| EP4494700A3 (en) | New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases | |
| JP2009534367A5 (OSRAM) |